Cross Border Collaboration delivers International Award for High Design Quality: Randox Discovery, The Benchtop Lab receives Red Dot Design Award
Cross Border Collaboration delivers International Award for High Design Quality: Randox Discovery, The Benchtop Lab receives Red Dot Design Award
Cross Border Collaboration delivers International Award for High Design Quality: Randox Discovery, The Benchtop Lab receives Red Dot Design Award
The Randox Discovery, an exciting and unique diagnostic analyser which can consolidate molecular and immunoassay testing on one compact benchtop platform, has received the 2021 Red Dot Award for High Design Quality.
Red Dot, which has become established as one of the top profile product design awards has roots dating back as far as 1955 and determines the best products created each year. Recognised as one of the largest global product competitions for innovation excellence, this sought-after seal for quality design attracts submissions from over 50 countries, across 49 different categories including medical devices and technology.
Dr Stuart Jackson, Randox Project Design Engineer, commented;
“Randox are delighted to have achieved the Red Dot design award, the culmination of five years of development and coordination of engineering design teams spanning two continents. The Discovery is a particularly unique innovation capable of automating Randox Biochip molecular diagnostics assays, from sample lysis and end-point PCR to multiplexing detection, with accessibility and ease-of-use at the forefront of the design.”
Dolmen were briefed by the Randox team to develop a creative and dynamic way to showcase the cutting-edge inner workings of the Discovery. Essentially, to turn the magic of the machine into a piece of theatre; not just a tool, but the centre of attention, a focal point for the lab that has excellent usability and accessibility throughout. Dolmen and Randox collaborated closely to deliver a revolutionary instrument that, amongst its many abilities, is a COVID-19 diagnostic analyser that is the first of its kind.
Chris Murphy, CEO and Design Director, Dolmen Design and Innovation, commented;
“We are delighted that our collaboration with Randox has delivered another Red Dot design award for our team. Randox as a team truly value the power of design and how it can deliver better outcomes for end users. It is also wonderful to see our designs delivering positive change at the frontline of the COVID pandemic. This project was hugely collaborative, and we look forward to more collaborations in the future.”
What makes the Discovery special is its ability to conduct the full testing process, inclusive of sample preparation techniques such as extraction, purification, amplification and detection, in one highly intelligent, fully integrated space. The preparation of COVID-19 samples before testing was once lengthy and time-consuming, requiring a separate, sterilized laboratory for each stage, but can now be conducted on-board and by the fully automated Discovery platform, allowing a single operator to run multiple molecular tests simultaneously.
Combining almost 40 years of diagnostics into one platform, bringing multiple labs into one the COVID-19 diagnostic analyser is the first of its kind to combine sample preparation techniques and Biochip Technology.
Professor Dr. Peter Zec, Red Dot CEO, commented;
“The winners of the Red Dot Award: Product Design 2021 were particularly impressive this year. The design of their products is excellent, in terms of both the aesthetic and the functionality. It’s not easy to prevail in such a strong field of competitors and to win over our jury. Consequently, I want to congratulate the laureates very sincerely on their success.”
For further information please email randoxpr@randox.com
Want to know more?
Contact us or visit our find out more about the Randox Discovery
Related Products
Randox Discovery
COVID 19 Product Overview
COVID 19 QPCR ASSAY
VIRAL RNA EXTRACTION KIT
BioReagents
BioReagents
Randox Biosciences have been a world-leading primary manufacture of high quality antibodies, proteins and conjugates for over 40 years.
With an extensive portfolio of over 900 high quality monoclonal and polyclonal antibodies, antibody fragments including sdAb’s, scFv’s and fAb’s, human recombinant proteins and conjugates, allow us to successfully assist with any new product development, research and partnership needs.
Our team of scientists possess unrivaled expertise which enables us to provide you with a comprehensive suite of products and services dedicated to advancing biopharmaceutical research and diagnostics. A custom development service is also available.
From initial cultivation of raw materials for assay development, through to providing companion diagnostics, custom and molecular based assays across a range of therapeutic areas; Randox BioReagents is a trusted partner supplying quality diagnostic solutions to the clinical, life science, pharmaceutical, research and biopharma industries.
We take pride in our development and quality, which reflect the components used in-house in the product of Randox diagnostics and research. With many unique and novel solutions for a wide range of applications, our standards not only meet unmet market needs but the ability to offer a world-class service meeting all customer requirements including custom developments upon request, in a wide range of pack sizes, producing excellent reproducibility, higher sensitivity and specificity for a multitude of projects.
Our Range of BioReagents
Randox Professor of Medicine: Ulster University Announces Creation of New Role at Brand New School of Medicine
Wednesday 23 June 2021
Ulster University Announces Creation of New Role at Brand New School of Medicine: the Randox Professor of Medicine
Ulster University has received £1.2million in funding for medical education and research from Randox Laboratories Ltd. Thanks to this generous donation from Randox Laboratories, the University is creating its first Professor of Medicine post, to be titled, the Randox Professor of Medicine.
This will be a clinical and academic post so the appointee to the Randox Professorship will provide educational leadership, teaching and training thus inspiring the next generation of doctors and researchers in the area.
Alongside education, the post holder will develop a research portfolio in line with the research strategy of the School of Medicine and ambitions included in the Health Research Institute-THRIVE (HRI-THRIVE) Project as part of the Derry and Strabane City Deal.
The successful appointee to the Randox Professorship will have an outstanding track-record in medical research with the experience, vision and enthusiasm to build on current strengths in the University and develop a leading research presence in the School of Medicine.
The Randox Professor will be part of a vibrant and intellectually stimulating translational research community both within the School of Medicine and C-TRIC and will have access to the leading research facilities which the University offers. They will have the opportunity to collaborate with existing researchers in personalised medicine and influence the research and innovation direction of the proposed THRIVE Research Units that currently include: Blood Cancer; Cardiovascular Research and Improvement Science; Neuromuscular Health (Motor Neuron Disease, MS, Parkinson’s Disease); Brain Health (Depression, psychosis, Alzheimer’s Disease); Orthopaedic and Rheumatic Health; and Multiple Long-term Conditions.
The Randox professor will deliver clinical care within the Western Trust, contributing directly to patient care and improving health outcomes for our local community.
Dr Catherine McDonnell, Medical Director at the Western Trust, is excited at the new appointment:
“This is a unique opportunity, and shows what can be achieved with collaborative working and by forging partnerships between organisations.
“The Randox Professorship will play a crucial role in the delivery of patient care in the months and years ahead, and will help us bring in fresh expertise to what is already a very strong team on the ground.
“We would like to thank both Ulster University and Randox Laboratories for partnering in this exciting venture, which we believe will have a very positive impact on our patients and the Western Trust overall.”
Pictured left to right are Dr Peter FitzGerald, Managing Director, Randox Laboratories, and Professor Paul Bartholomew, Vice-Chancellor at Ulster University
The post will report into the Foundation Dean of the School of Medicine and recruitment will commence in the coming weeks.
The role will be supported by Randox Laboratories for a period of 5 years.
Dr Peter FitzGerald, Managing Director, Randox Laboratories said:
“At this time of rapid and significant change within medicine, it is imperative that industry, academia and medical education are aligned to improve both patient outcomes and the efficiency of healthcare services. The announcement of the new post of Randox Professor of Medicine within the new Ulster University School of Medicine shows our commitment to these critical national priorities. Ulster University and Randox are both renowned globally for healthcare research and education, particularly in the field of diagnostics, and together provide a vital platform to support the next generation of aspirational clinicians – to develop critical skills, make a positive difference to patient healthcare around the world, and cement Northern Ireland’s reputation as a global hub for life sciences.”
Professor Paul Bartholomew, Vice-Chancellor at Ulster University added:
“By opening the School of Medicine in August we are committing to address the acute shortage of doctors in Northern Ireland and to recruit students and staff who will be locally focused yet globally ambitious. The appointment of the Randox Professor of Medicine will enable us to further this ambition and allow us to enhance the University’s existing expertise and research excellence in personalised medicine diagnostics and contribute to expanding the medical diagnostics sector. With the strong emphasis on personalised medicine in the Derry and Strabane City Deal, the Randox Professor of Medicine will join us at an exciting time for the region.
“The University sees the ground breaking Randox Professorship as an opportunity to further our long standing partnership with Randox so that we might together have a unique opportunity to support clinical medicine, enhance the quality of patient care through highly relevant translational research and inspire the next generation of doctors.”
Professor Louise Dubras, Foundation Dean, School of Medicine at Ulster University, added:
“As we look forward to our first students arriving in August this year, we are excited to be progressing this role, the first of our “second wave”, to complement the exceptional staff team in place to deliver the first year of the programme. This is a unique and exciting opportunity for an inspirational academic clinical leader to shape the direction of clinical and translational research within the School of Medicine. I’m looking for an outstanding candidate with a wealth of teaching experience and a passion for related research which will inform teaching. This candidate will join me and the incredible team we have put together to teach the doctors of the future.”
For press enquiries please contact Amy Millar in the Randox PR team on amy.millar@randox.com or 028 9442 2413
Want to know more?
Contact us or visit Ulster University.
Related Pages
ABOUT RANDOX
NEWS
VACANCIES
OUR PEOPLE
Randox Biosciences Launch New Website
Randox Biosciences is delighted to officially announce the launch of our new website which offers a sleek, simple yet informative platform to further your knowledge of our product range and how we can assist you.
After six months of hard work and dedication the website has a fresh look. The interactive aspect of the website provides an easy way for our visitors to learn about Randox Biosciences products and services.
The improved interactive navigation ensures the user enjoys a seamless transition through Randox Biosciences extensive range of products and services with a better experience for both mobile and desktop versions. Potential customers will be able to identify with ease which client segment they fit into – whether it be Academic Research, Biopharma or Clinical Laboratory, enjoying a fully responsive experience.
During the redesign of the Randox Biosciences website we ensured that the brand identity remained consistent throughout, incorporating the brand colours across the site. We in cooperated GIFS (Graphics Interchange Format or moving images) on the top of the homepage as the main header of the website to automatically attract visitors with a moving graphic.
The GIF represents the Biochip Array Technology and the two different diagnostics testing we offer at Randox Biosciences. The GIFs images were continued throughout the website to highlight the three industries we cater for. Brochure downloads are also available on the new website for customers to enhance their knowledge with more in-depth information of Randox’s products and services.
The incorporation of an overview video on the homepage enables website users to gain a snapshot view of Randox Biosciences products and services. The idea of presenting the video first is to allow the visitor to understand our company from a visual method rather than processing a lot of written information.
73% of consumers worldwide would prefer seeing a video than text because they are more “entertaining”.1 The video itself, captures exactly what Randox Biosciences is and what we do. A short yet effective video clearly illustrates the science behind of Randox Biosciences and how this reaches the patient through drug discovery and development.
Julie-Ann O’Hare, Director of Randox Biosciences, commented:
“I am thrilled with the final product of the website, which I hope our current and potential customers will utilise it with ease. The website is another aspect of aligning our marketing strategy and branding to ensure our messaging is clear, concise and consistent across the board. We look forward to the continuation of promoting Randox Biosciences in the digital landscape throughout 2019.”
An e-commerce section of the website is under construction for the sale of our BioReagent products, which they are very excited to launch upon completion in Q3.
Check out our new and improved website for yourself. It is available at: https://www.randoxbiosciences.com/. Also, to find out more email us at info@randoxbiosciences.com
- http://rocketium.com/academy/6-reasons-why-customers-prefer-video-ads-to-the-text-ones
UK Research and Innovation CEO Sir Mark Walport visits Randox
From cybersecurity and immersive technologies to restoration Shakespeare, new diagnostic tools and aerospace, Northern Ireland is home to world class research and innovation.
UK Research and Innovation (UKRI) is celebrating excellence in Northern Ireland by showcasing some of the leading work taking place in the country ahead of an engagement event in the Ormeau Baths on the evening of Tuesday 29th January 2019.
Ahead of the event, UKRI Chief Executive Professor Sir Mark Walport paid a visit to the Randox Science Park in Antrim, to learn more about the innovative diagnostic technologies we develop for hospitals, clinical, research and molecular labs, food testing, forensic toxicology, veterinary labs and life sciences.
UKRI Chief Executive Professor Sir Mark Walport said:
“Research and innovation excellence in Northern Ireland plays an important role in the UK’s success on the world stage. Its universities, innovation networks and leading businesses are an integral part of the UK’s research landscape. With UKRI support, they are pushing boundaries in areas such as healthcare, digital technologies and aerospace.”
The visit by Sir Walport follows our announcement in December 2018 that UKRI had awarded Randox a grant of £700,000 as part of the Industrial Strategy Challenge Fund (ISCF) to further develop our state-of-the-art ‘freeze-drying’ technology. This enables the components of vital diagnostic kits to be manufactured, stored and transported more effectively, producing better and speedier diagnoses.
Earlier in the year we also announced a £50 million investment in three new research and development Centres of Excellence for clinical diagnostics.
The UKRI reception at Ormeau Baths, which is now home to a Digital Catapult Centre, supporting the innovation community in the heart of Belfast, will celebrate Randox research projects such as the Centres of Excellence, as well as those of other companies in Northern Ireland, including a £13 million collaboration to boost the flourishing creative sector, part of the £80m UK-wide Creative Cluster programme. Current UKRI investment in Northern Ireland includes more than £78 million invested in active research projects.
The event celebrates the diverse research and innovation excellence in Northern Ireland and is an opportunity to discuss future ambitions.
It will be hosted by Professor Walport, with speakers including David Sterling, Head of the Civil Service of Northern Ireland; Professor Paddy Nixon, Vice-Chancellor and President of Ulster University; and Professor Máire O’Neill, Institute of Electronics, Communications & Information Technology at Queen’s University Belfast, and follows Sir Mark Walport’s visit to Randox Laboratories and also Bombardier, the world’s leading manufacturer of both planes and trains.
We were delighted to host Sir Mark Walport at the Randox Science Park and are looking forward to celebrating the success of Northern Ireland research and development at the UK Research and Innovation event this evening.
For further information please contact Randox PR by phoning 028 9442 2413 or emailing randoxpr@randox.com
£700,000 UK government investment in Randox R&D
A £700,000 UK Research and Innovation investment into manufacturing processes at Randox means patients could benefit from quicker, cheaper and more consistent diagnosis of diseases.
The announcement comes exactly one year after the government launched its modern Industrial Strategy – the long-term plan to boost productivity by backing businesses to create high-quality, well-paid jobs in every corner of the United Kingdom.
The Industrial Strategy Challenge Fund (ISCF) award, administered by UK Research and Innovation (UKRI), will allow Randox Laboratories to further develop its state-of-the-art ‘freeze-drying’ technology which enables the components of vital diagnostic kits to be manufactured, stored and transported more effectively, producing better and speedier diagnoses.
For the first time it also allows this complicated manufacturing process to be carried out in the UK rather than having to be outsourced to countries such as the United States, bringing more jobs and economic growth. These new genomic analysis tools also have the potential to make a major impact in the global fight against antimicrobial resistance by identifying and quickly sharing information about resistant microbial strains.
More in-depth analysis of biomarkers in blood and other bodily fluid levels will allow better, quicker diagnosis of cancers and a range of other diseases, ranging from respiratory infections to sepsis, such as blood poisoning.
The Secretary of State for Northern Ireland said:
“I am delighted to announce a £700,000k UK Government investment in Randox, a multinational life sciences company in County Antrim. This funding will bring significant benefits to Randox’s vital medical diagnostics and help create well-paid manufacturing jobs in Northern Ireland.
“A year-on from the launch of our Modern Industrial Strategy, this investment highlights the great progress we are making to boost productivity by backing leading businesses and creating high-quality jobs in every corner of the United Kingdom.”
John Penrose, Minister of State for Northern Ireland, who visited Randox today to mark the new investment, said:
“Everyone always says the UK needs more high-tec, high-value added manufacturing and the high-skilled, high-waged jobs it brings. But Randox are actually doing it right here in Northern Ireland. This is properly world leading, cutting-edge industry and I’m delighted that today’s money is helping bring the vision to life.”
Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented:
“Innovative diagnostic technologies are not only capable of diagnosing disease and ill-health at the earliest possible stage, but they also have a real potential to advance personalised medicine. Our commitment to developing new and exciting breakthroughs in science, technology, engineering and manufacturing is therefore matched only, by our passion to transform the life of the patient. Randox is leading the way in moving from a one-size-fits-all approach towards decisions, practices, and products tailored to the needs of the individual and the Industrial Strategy Challenge Fund award brings us one step closer to realising that aim.”
Funded through UK Research and Innovation, the award forms part of the ISCF Early Diagnosis and Precision Medicine programme, focusing on the use of diagnostic information and genetic analysis to drive more personalised healthcare. Innovate UK, now part of UK Research and Innovation, has supported Randox extensively since 2010, helping grow and scale an innovative diagnostics company who are now distributing their products all over the world.
The announcement comes after the government’s announcement of the Life Sciences Sector Deal that will support healthcare innovation and back businesses to create high-paid, high-quality jobs as part of the government’s modern Industrial Strategy. The deal signals a vote in confidence in UK industry, with global biopharmaceutical company UCB investing around £1 billion in research and development.
For further information please contact Randox PR by emailing randoxpr@randox.com
Metabolic Syndrome Array II Quality Control
A multi-analyte quality control with target values and ranges provided for 3 parameters associated with metabolic syndrome.
Features & Benefits
- Lyophilised for enhanced stability
- 100% human material
- Stable to expiry date at 2oC – 8oC
- Reconstituted stability of 72 hours at 2oC – 8oC and 7 days at -20°C
- Assayed values available for Randox Biochip systems
| Description | Size | Analytes | Cat No | |
|---|---|---|---|---|
| Metabolic Syndrome Array II Control | 3 x 3 x 1ml | 3 | EV3761 | |
| Metabolic Syndrome Array II Calibrator | 9 x 1 ml | 3 | EV3760 |
Analytes
- Adiponectin
- CRP
- Cystatin C
Randox collaboration with Centre for Personalised Medicine is officially launched
A €8.6m EU funded cross-border Centre for Personalised Medicine that will improve clinical decision making and patient safety for dementia, diabetes, cardiovascular, acute kidney injury and emergency surgery has been officially launched.
Funded by the European Union’s INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB), the Centre for Personalised Medicine brings together 14 academic, healthcare provider and enterprise partner organisations, including Randox Laboratories, to work together to deliver practical solutions to clinicians to ensure that patients get the right treatment at the right time.
Personalised medicine moves away from the ‘one size, fits all’ approach, using state of the art genomics testing, technology and computing and intelligence systems to deliver a more targeted approach.
Lead investigator of the Centre, Professor Tony Bjourson, Professor of Genomics at Ulster University and Director of the Northern Ireland Centre for Stratified Medicine said:
“The Centre for Personalised Medicine will bring personalised medicine approaches to five of the most prevalent disease areas to improve the care and treatment of patients in Northern Ireland, the border region of Ireland and Western Scotland. This collaboration extends partnership working to key clinicians in the health sector ensuring that we address real world issues across the five disease areas.”
Dr Kenneth Martin, Senior R&D Scientist at Randox Laboratories, explained Randox’s role in the Centre for Personalised Medicine;
“Our highly committed R&D programme here at Randox means that we have more than 490 new tests currently in development – more than any other diagnostics company – across a range of pressing health challenges, including dementia, cardio-metabolic syndrome and renal disease. These tests, developed on our patented Biochip Array Technology which can conduct multiple patient tests simultaneously, can work to identify patients who will benefit from tailored therapeutics for enhanced efficacy. The CPM project will use Randox Arrays in four of the five research clusters in the project to determine how the information they provide can benefit clinical decision making. We aim to provide clinicians with the tools they need to make more accurate and better-informed decisions for their patients. This means that countermeasures can be taken at the earliest possible opportunity, when treatment is most likely to succeed.”
Welcoming the project Gina McIntyre, CEO of the Special EU Programmes Body, said:
“This project reflects one of the core objectives of the INTERREG VA Programme, to improve access to healthcare services for thousands of citizens. It has great potential as it will bring together a diverse range of cross-border partners to significantly improve clinical decision-making, and personalised treatment approaches, in the fight against five of the most common diseases.”
Match-funding for this project has been provided by the Department of Business, Enterprise and Innovation in Ireland and the Department for the Economy in Northern Ireland.
For more information on the Centre for Personalised Medicine please contact the Randox PR team on 028 9442 2413 or by emailing randoxpr@randox.com
Randox pioneers health testing innovations at world’s largest diagnostics conference
World-leading medical diagnostics manufacturer Randox Laboratories is this week showcasing advancements in biotechnology at the world’s largest diagnostics conference, being held in Chicago, Illinois.
The American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, known as the leading event for laboratory medicine worldwide, offers Randox the opportunity to showcase their capabilities to more than 20,000 healthcare professionals and decision makers from around the globe.
“Our pioneering diagnostic technologies are leading the way in innovation and have real potential to transform healthcare around the world,” said Randox Managing Director, Dr Peter FitzGerald.
“At AACC we will be hosting demonstrations of a wide range of our intuitive multiplex analysers, including the revolutionary Randox Evidence Evolution, the world’s first fully automated random-access testing platform, capable of delivering 2640 results in one hour, with the first delivered in just 37 minutes.”
The unique and unrivalled capabilities of the Randox Evidence Evolution are made possible thanks to Randox’s patented Biochip Array Technology, which can currently run 49 different tests simultaneously – ensuring an accurate and reliable diagnosis as fast as possible.
Launching at this year’s AACC event are a number of exciting new tests on the Randox Biochip, the result of a £280 million investment in research and development. Including but not exclusive to a diagnostic test for the differentiation of hemorrhagic and ischemic strokes, an algorithm capable of generating a patient’s Type 1 Diabetes Genetic Risk Score, and a test to diagnose Acute Kidney Injury (AKI) in the participants of pharmaceutical drug trials, these new tests all share the common goal of much earlier and effective diagnosis, to greatly improve healthcare outcomes and reduce the burden on healthcare services.
Dr. FitzGerald continued;
“We remain committed to developing new health diagnostic technologies for a range of the world’s most pressing health issues in need of the most urgent address, and to expanding the business in our key markets, such as the US.
“Our very significant investment in research and development means that we have more new tests in development than any other healthcare company in the world and are able each year to bring a wealth of exciting new technologies to the American market.
“We look forward to showcasing our latest innovations at this year’s AACC conference, and how they can be utilised to save, improve and extend lives through the earliest possible diagnosis. Randox technology can truly revolutionise the future of healthcare.”
AACC runs from the 29th July – 2nd August at McCormick Place in Chicago, Illinois. Randox can be found at booth #3624.
For further information visit aacc.randox.com
Randox Biosciences: dedicated to advancing scientific discovery
Randox Laboratories is an international clinical diagnostic solutions company with over 35 years’ experience in the industry. Randox is a global market leader, providing revolutionary products for laboratories worldwide and is dedicated to improving health.
Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. Spanning four key divisions; Life Sciences, Pharma Sciences, Research and Molecular; Randox Biosciences offers complete tailored solutions for clinical and research use.
From initial cultivation of raw materials for assay development, through to providing companion diagnostics, custom and molecular based assays across a range of therapy areas; Randox Biosciences is a trusted partner supplying quality diagnostic solutions to the clinical, life science, pharmaceutical, research and biopharma industries. We specialise in supplying academic centres, genetics laboratories and the global biopharmaceutical industry with products tailored to their specific needs.
Randox Biosciences Research team encompasses a knowledgeable group of who are dedicated to assisting your research project to completion. Recently, the research team has expanded to include Business Development Executives in America to support academic centres of excellence achieve their potential while utilising our quality products. We are proud to welcome Rebecca Newburg who will be focusing her efforts on the US-Midwest market and Celestine Eshiet who will be working on the US -West Coast.
We cover five areas of research such as Sport and Exercise, Cardiovascular, Metabolic, Immunology and Oncology. These five areas include our Metabolic Syndrome Array 1 & 2, Cytokine Arrays and Cardiac Array including CK-MB, H-FABP, Myoglobin and Troponin.
If you work in an academic centre and are interested in our variety of arrays, analysers whether that be chemistry or immunoassay analysers, or our reagents or quality control please do not hesitate to contact us at info@randoxbiosciences.com.
